Efficacy and safety of enzalutamide, abiraterone and cabazitaxel in post-docetaxel treatment of castration-resistant prostate cancer: meta-analysis data

Author:

Mazin P. V.,Mazina N. K.

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference31 articles.

1. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359–86. DOI: 10.1002/ijc.29210. PMID: 25220842.

2. Yoo S., Choi S., You D., Kim C.S. New drugs in prostate cancer. Prostate Int 2016;4(2):37–42. DOI: 10.1016/j.prnil.2016.05.001. PMID: 27358841.

3. Chissov V.I., Rusakov I.G. Zabolevaemost' rakom predstatel'noi zhelezy v Rossiiskoi Federatsii. Eksperimental'naya i klinicheskaya urologiya 2011;(2–3):6–7. [Chissov V.I., Rusakov I.G. Prostate cancer morbidity in Russia. Eksperimental’naya i klinicheskaya urologiya = Experimental and Clinical Urology 2011;(2–3):6–7. (In Russ.)].

4. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi. M.: MNIOI im. P. A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii, 2018. 250 s. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].

5. Engalychev F.Sh., Mironov M.A., Galkina N.G., Lyamkin S.V. Statisticheskie dannye po raku prostaty v Penzenskoi oblasti za 2005–2009 gody. Materialy V Kongressa Rossiiskogo obshchestva onkourologov, 2010. Dostupno po: www://roou.ru/.uploads/press/tezis/292/5_Congress_Oncourologyinet27. file27.file.pdf. [Engalychev F.Sh., Mironov M.A., Galkina N.G., Lyamkin S.V. Statistical data on prostate cancer in Penza Region in 2005–2009. Proceedings of the V Congress of the Russian Association of Oncological Urology, 2010. Available at: www://roou.ru/.uploads/press/tezis/292/5_Congress_Oncourologyinet27. file27.file.pdf (In Russ.)].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3